Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWRD06 in postoperative GPC3-positive hepatocellular carcinoma (Phase II)
CTR20254905Phase 2Active
- Sponsor
- Nuowei Technology
- Start
- Dec 2025
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NWRD06 in hepatocellular carcinoma (HCC), sponsored by Nuowei Technology. Started Dec 2025; status: active.
02
Drugs
NWRD06
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20254905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254905.